Bipolar medication is chosen differently for mania, for depression and for staying well, and the evidence is different for each. A 2011 analysis of 68 trials found haloperidol, risperidone and olanzapine outperformed other drugs in acute mania, [cipriani-2011] while a 2014 meta-analysis concluded that lithium remains the most valuable option for preventing new episodes. [severus-2014] This guide covers what the main reviews found for each phase, where the picture is weaker, what the reviews could not show and what to ask a prescriber. Our overview of bipolar disorder covers the condition and the wider approach to treatment.
What medication works for mania?
For acute mania, antipsychotics did best and lithium and valproate were effective but not at the top. A 2011 multiple-treatments meta-analysis compared 14 drugs and placebo across 68 trials. Haloperidol (standardised mean difference, SMD, -0.56), risperidone (-0.50), olanzapine (-0.43), lithium (-0.37), quetiapine (-0.37), aripiprazole (-0.37), carbamazepine (-0.36), asenapine (-0.30), valproate (-0.20) and ziprasidone (-0.20) were significantly more effective than placebo, whereas gabapentin, lamotrigine and topiramate were not. [cipriani-2011]
The authors’ summary is that haloperidol, risperidone and olanzapine outperformed other drugs on efficacy, while olanzapine, risperidone and quetiapine led to significantly fewer discontinuations than lithium, lamotrigine, placebo, topiramate and gabapentin. [cipriani-2011] A drug that works well but is stopped early because it is hard to tolerate is not the same as one that people can stay on, which is why the review reports both.
Standardised mean differences versus placebo for selected drugs in acute mania, Cipriani et al. (2011), multiple-treatments meta-analysis of 68 trials. The reported values are negative (haloperidol -0.56, risperidone -0.50, olanzapine -0.43, lithium -0.37, carbamazepine -0.36, valproate -0.20); bars show their size, and a larger bar means a larger benefit.
What medication works for bipolar depression?
Several antipsychotics and one anticonvulsant did, but much of the wider evidence is weak. A 2023 network meta-analysis analysed 101 randomised trials with 20,081 participants and 68 medications or dietary supplements. It found that olanzapine plus fluoxetine, quetiapine, olanzapine, lurasidone, lumateperone, cariprazine and lamotrigine were efficacious in reducing depressive symptoms, with small-to-medium effect sizes and good quality evidence. [yildiz-2023]
Some other interventions might also work, but the quality of the evidence was low or very low, mainly because of imprecision and small samples. Antidepressants and, with a smaller effect size, antiepileptics as classes could be almost as efficacious as antipsychotics, although larger trials are needed to confirm this. [yildiz-2023]
The side-effect picture differs too. None of the medications clearly increased the risk of switching to mania, but antidepressants as a class had a higher risk than antipsychotics, and quetiapine clearly decreased it on good quality evidence. Antipsychotics were associated with multiple side-effects with differing profiles, while lamotrigine may have a more benign profile but may also be less efficacious. [yildiz-2023]
Does lithium prevent new episodes?
Yes, on average, and it is the best-supported drug for that job. A 2014 meta-analysis of 7 trials with 1,580 participants found lithium more effective than placebo at preventing overall mood episodes (risk ratio 0.66, 95% confidence interval 0.53 to 0.82) and manic episodes (0.52, 0.38 to 0.71). For depressive episodes the result depended on the analysis: 0.78 (0.59 to 1.03) with a random-effects model and 0.73 (0.60 to 0.88) with a fixed-effect model. [severus-2014]
The costs show up in the same data. People on lithium were more likely than people on placebo to drop out for reasons other than a mood episode (risk ratio 1.33), though they were also more likely to complete the study (1.69). Against anticonvulsants, in 7 trials with 1,305 people, lithium prevented manic episodes better (0.66, 0.44 to 1.00), with no significant difference for overall or depressive episodes. [severus-2014]
The authors concluded that no other drug has such ample and consistent evidence for this use, and that lithium remains the most valuable treatment option for long-term prevention. [severus-2014]
| Phase | Best-supported options in these reviews | How firm |
|---|---|---|
| Acute mania | Haloperidol, risperidone, olanzapine (then lithium, quetiapine and others) | 68 trials, 2011 analysis |
| Bipolar depression | Olanzapine plus fluoxetine, quetiapine, olanzapine, lurasidone, lumateperone, cariprazine, lamotrigine | 101 trials; good quality for these, low for many others |
| Preventing new episodes | Lithium | 7 trials against placebo; weaker for depressive episodes |
What can this research not show?
It cannot show which drug will suit you, how to manage side-effects or what happens over decades. Five limits matter most:
- The mania analysis is old. It was published in 2011 and compared 14 drugs, so later trials and newer drugs are not in it. [cipriani-2011]
- Efficacy is not the same as staying on a drug. The review reports discontinuations separately, and the best-performing drug for symptoms was not the best for staying on treatment. [cipriani-2011]
- Much depression evidence is thin. For some interventions among the 68 the quality of evidence was low or very low, and the authors said larger trials are required to confirm the finding on antidepressants. [yildiz-2023]
- The lithium result for depression is not clear-cut. It crosses the line of no effect in one analysis and not in the other, and people on lithium were more likely than people on placebo to drop out for reasons other than a mood episode. [severus-2014]
- Nothing here covers monitoring, pregnancy or children. The reviews we could verify did not address blood tests, pregnancy or young people, so these are questions for a prescriber.
What should you ask a prescriber?
Ask which phase the medication is for, what the plan is if it does not work and what to watch for in the first weeks. This section is our suggestion and is not something the reviews tested.
Useful questions are what side-effects to expect and how they will be monitored, whether an antidepressant is part of the plan and what happens about the risk of switching into mania, and how you will know it is working. Do not stop a prescribed mood stabiliser or antipsychotic suddenly without speaking to the prescriber. Our guides to hypomania and bipolar and sleep cover warning signs worth recording, and how to support someone with bipolar disorder covers the other side of the conversation.
No screener on this site covers bipolar disorder. The self-assessment hub lists the seven we do have, and none is built for this question, so do not use a depression screener as a substitute.
When to seek help
Speak to a doctor promptly if you have several days of unusually high energy, little need for sleep and racing thoughts, or if low mood has become heavy or hopeless, especially if you have already been diagnosed and your medication is not working. If you feel unable to stay safe, contact your local emergency services or a crisis helpline.
How MyFreud can help
Sleep and mood patterns are often the first thing a prescriber wants to see. Daily mood tracking in MyFreud shows how your days run over weeks, and the notepad is somewhere to note sleep, medication changes and early warning signs. It does not replace a doctor or a prescriber.
Download MyFreud and start today: App Store or Google Play.